BL9B Stock Overview Develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. More details
Rewards Risk Analysis No risks detected for BL9B from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Balchem Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Balchem Historical stock prices Current Share Price US$153.70 52 Week High US$174.90 52 Week Low US$127.70 Beta 0.69 1 Month Change -2.97% 3 Month Change 1.12% 1 Year Change 18.41% 3 Year Change 18.14% 5 Year Change 55.96% Change since IPO 616.55%
Recent News & Updates
Balchem Corporation Announces Dividend, Payable on January 17, 2025 Dec 11
Third quarter 2024 earnings released: EPS: US$1.03 (vs US$0.91 in 3Q 2023) Oct 26
Balchem Corporation Announces Resignation of Joyce Lee as Director Oct 18
Balchem Corporation to Report Q3, 2024 Results on Oct 25, 2024 Oct 11
Now 21% overvalued after recent price rise Jul 30
Second quarter 2024 earnings released: EPS: US$0.98 (vs US$0.94 in 2Q 2023) Jul 28 See more updates
Balchem Corporation Announces Dividend, Payable on January 17, 2025 Dec 11
Third quarter 2024 earnings released: EPS: US$1.03 (vs US$0.91 in 3Q 2023) Oct 26
Balchem Corporation Announces Resignation of Joyce Lee as Director Oct 18
Balchem Corporation to Report Q3, 2024 Results on Oct 25, 2024 Oct 11
Now 21% overvalued after recent price rise Jul 30
Second quarter 2024 earnings released: EPS: US$0.98 (vs US$0.94 in 2Q 2023) Jul 28
Balchem Corporation to Report Q2, 2024 Results on Jul 26, 2024 Jul 13
Independent Director recently sold €712k worth of stock May 12
First quarter 2024 earnings released: EPS: US$0.89 (vs US$0.71 in 1Q 2023) May 03
Balchem Corporation, Annual General Meeting, Jun 20, 2024 Apr 28
Balchem Corporation to Report Q1, 2024 Results on May 03, 2024 Apr 21
Chairman recently sold €4.2m worth of stock Feb 26
Full year 2023 earnings released: EPS: US$3.38 (vs US$3.29 in FY 2022) Feb 18
Balchem Corporation to Report Q4, 2023 Results on Feb 16, 2024 Feb 03
Now 21% overvalued after recent price rise Feb 01
Upcoming dividend of US$0.79 per share at 0.6% yield Dec 19
Balchem Corporation Announces Dividend, Payable on January 19, 2024 Dec 06
Third quarter 2023 earnings released: EPS: US$0.90 (vs US$0.79 in 3Q 2022) Oct 28
Balchem Corporation to Report Q3, 2023 Results on Oct 27, 2023 Oct 14
Independent Director recently sold €465k worth of stock Sep 13
Balchem Corporation Announces Board Appointments, Effective as of September 6, 2023 Sep 08
Second quarter 2023 earnings released: EPS: US$0.94 (vs US$0.93 in 2Q 2022) Jul 30
Balchem Corporation to Report Q2, 2023 Results on Jul 28, 2023 Jul 15
Senior VP & CTO recently sold €273k worth of stock May 07
First quarter 2023 earnings released: EPS: US$0.71 (vs US$0.90 in 1Q 2022) Apr 30
Independent Director recently sold €356k worth of stock Mar 23
Full year 2022 earnings released: EPS: US$3.25 (vs US$2.98 in FY 2021) Feb 26
Balchem Corporation to Report Q4, 2022 Results on Feb 24, 2023 Feb 11
Upcoming dividend of US$0.71 per share Dec 16
Balchem Corporation Announces Dividend, Payable on January 20, 2023 Dec 07
Insufficient new directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.78 (vs US$0.78 in 3Q 2021) Nov 05
Insufficient new directors Nov 01
Balchem Corporation to Report Q3, 2022 Results on Nov 04, 2022 Oct 22
Insufficient new directors Oct 02
James C. Hyde, Senior Vice President and General Manager, Human Nutrition & Health, Notifies Balchem Corporation His Intent to Retire from His Role Sep 30
Insider recently sold €173k worth of stock Aug 07
Second quarter 2022 earnings released Jul 30
Balchem Corporation to Report Q2, 2022 Results on Jul 29, 2022 Jul 16
Balchem Corporation (NasdaqGS:BCPC) completed the acquisition of Kappa Bioscience AS from Verdane Edda managed by Verdane and others on June 21, 2022. Jun 22
Balchem Corporation (NasdaqGS:BCPC) entered into an agreement to acquire Kappa Bioscience AS from Verdane Edda managed by Verdane and others. Jun 15
Balchem Corporation Announces Resignation of Mark Stach as Company Secretary Jun 09
Balchem Corporation, Annual General Meeting, Jun 23, 2022 May 02
First quarter 2022 earnings released: EPS: US$0.89 (vs US$0.73 in 1Q 2021) May 01
Balchem Corporation to Report Q1, 2022 Results on Apr 29, 2022 Apr 16
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 19
Balchem Corporation to Report Q4, 2021 Results on Feb 18, 2022 Feb 05
Upcoming dividend of US$0.64 per share Dec 20
Third quarter 2021 earnings released: EPS US$0.78 (vs US$0.67 in 3Q 2020) Oct 31
Insider recently sold €946k worth of stock Aug 11
Second quarter 2021 earnings released: EPS US$0.70 (vs US$0.66 in 2Q 2020) Jul 31 Balchem Corporation(NasdaqGS:BCPC) dropped from Russell 3000E Value Index
Independent Director Paul Coombs has left the company Jun 24
Independent Director Paul Coombs has left the company Jun 23
First quarter 2021 earnings released: EPS US$0.73 (vs US$0.61 in 1Q 2020) May 03
New 90-day high: €107 Mar 11
Full year 2020 earnings released Feb 21
Revenue beats expectations Feb 21
Paul Coombs Not Stands for Re-Election as Member of Class 2 of the Board of Balchem Corporation Feb 13
Balchem Corporation to Report Q4, 2020 Results on Feb 19, 2021 Feb 06
New 90-day high: €94.60 Jan 05
New 90-day high: €91.00 Dec 10
Insider recently sold €261k worth of stock Nov 19
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue beats expectations Oct 30
Balchem Corp Announces Retirement of Scott Mason, Vice President of Manufacturing and Supply Chain and Vice President and General Manager, Industrial Products Oct 17
Balchem Corporation to Report Q3, 2020 Results on Oct 28, 2020 Oct 15
New 90-day high: €90.10 Oct 13
New 90-day low: €79.05 Sep 18
Balchem Corporation to Report Q2, 2020 Results on Jul 31, 2020 Jul 21 Shareholder Returns BL9B DE Chemicals DE Market 7D 0.1% 2.2% 2.3% 1Y 18.4% 2.6% 11.9%
See full shareholder returns
Return vs Market: BL9B exceeded the German Market which returned 13.2% over the past year.
Price Volatility Is BL9B's price volatile compared to industry and market? BL9B volatility BL9B Average Weekly Movement 3.8% Chemicals Industry Average Movement 4.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: BL9B has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BL9B's weekly volatility (4%) has been stable over the past year.
About the Company Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Show more Balchem Corporation Fundamentals Summary How do Balchem's earnings and revenue compare to its market cap? BL9B fundamental statistics Market cap €5.09b Earnings (TTM ) €116.71m Revenue (TTM ) €904.97m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BL9B income statement (TTM ) Revenue US$942.38m Cost of Revenue US$617.52m Gross Profit US$324.86m Other Expenses US$203.32m Earnings US$121.54m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 3.74 Gross Margin 34.47% Net Profit Margin 12.90% Debt/Equity Ratio 19.3%
How did BL9B perform over the long term?
See historical performance and comparison Dividends
0.5% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/22 17:43 End of Day Share Price 2025/01/22 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Balchem Corporation is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Ishan Majumdar Baptista Research Robert Labick CJS Securities, Inc. Timothy Ramey D.A. Davidson & Co.
Show 8 more analysts 
